Plain-English translation of NCT07672119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study is looking at the heart-related risks for older men with advanced prostate cancer who have been treated with enzalutamide or darolutamide. While these medications can help control cancer, they may increase the risk of heart problems like heart attacks or strokes. Researchers want to understand how often these heart-related events happen and whether the risk differs between the two medications.
Doctors know that this medication can sometimes cause heart and blood vessel problems in men being treated for advanced prostate cancer, but it's not yet clear which patients are at highest risk or how the two different medications compare in terms of heart safety. This study will help doctors better understand these risks so they can make safer treatment choices.
You likely qualify if…
You likely don't qualify if…
This is not a treatment study—researchers will simply review your existing medical records from U.S. healthcare systems to track what happened during and after your prostate cancer treatment. There are no study visits, no extra blood tests, no extra doctor appointments, and no new medications. The study looks back at records from men who have already received these treatments as part of their regular cancer care.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States